LSTA · Lisata Therapeutics, Inc.
$1.00
-0.01 (-0.91%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and existing capital resources, management has concluded that there is substantial doubt regarding our ability to continue as a going concern for a period of twelve months from the date of issuance of the accompanying consolidated financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$8.97M
Shares
9.01M
Volume · Oct 23
45.56K
Avg daily vol (3M)
295.64K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.00
Open$1.00
Day$0.97–1.01
52W close$0.99–5.04
Avg vol 30d216K
Short int39K · 0.4% float · 1.0d
Short vol32%
Last earningsNov 6, 2025
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
call held Nov 6, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$100,000
Trailing 12 months
Net income (TTM)
−$14.62M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-16,428.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-137.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$10.44M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.8%
Year over year · more shares
Price change (1Y)
-57.6%
Trailing year
Short interest
0.4%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 19.5 · elevated
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−67%
below
Price vs 50-day avg
−29%
below
RSI (14)
34
neutral
MACD trend
Negative
52-week position
0%
near low
Momentum
relative strength
1-month return
−37%
trailing
6-month return
−70%
trailing
YTD return
−46%
this year
Relative strength
−76%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
4 of 33 funds reported for Sep 30 · net +11.3K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.44% of float · ▼ -76.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
33 holders — mid 3-yr range
Squeeze score
28
low risk · 0–100
Fundamentals
Revenue growth
+57%
Y/Y
Gross margin
5%
contracting
EPS growth
+20%
Y/Y
Free cash flow
$-16.0M
Balance sheet
$29.2M
net cash
Quant / Vol
risk profile
Volatility
131%
annualized · 1-yr
Max drawdown
−80%
past year
ATR
12.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−67%
Bearish
Price vs 50-day avg
−29%
Bearish
RSI (14)
34
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
4 of 33 funds reported for Sep 30 · net +11.3K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.44% of float · ▼ -76.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
33 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $5
vs 200-day avg -67%
vs 50-day avg -29%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LSTA
this stock
Lisata Therapeutics, Inc.
|
$8.97M | -46.5% | +56.9% | — | 0.4% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.80B | +15.6% | +46.2% | 30.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.88B | +4.3% | +20.8% | 19.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.89B | +578.5% | +4.3% | — | 7.7% |
|
CSLLY
Csl Ltd
|
$66.42B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
SEC Filings
Latest
DEF 14A
- Filed
- Oct 19, 2026
- This year
- 34
Lisata Therapeutics' proxy seeks stockholder approval for the conversion of Series C Preferred Stock issued in its completed Marea acquisition, a 1-for-5 to 1-for-15 reverse stock split, the 2026 Equity Incentive Plan and ESPP, and a planned rename to Marea Therapeutics, Inc. (symbol MREA).
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LSTA | -3.3% | -37.0% | -70.3% | -30.8% | -46.5% |
| SPY | -0.4% | -1.5% | +5.8% | -0.4% | +11.5% |
| vs SPY | -2.9% | -35.5% | -76.1% | -30.5% | -57.9% |